CC
AGMB

Casdin Capital’s AgomAb Therapeutics NV AGMB Stock Holding History

Casdin Capital’s Portfolio AGMB Stock Details AGMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.1M Hold
1,550,000
– – 1.01% 20
2026
Q1 		$16.3M Buy
+1,550,000
New +$22M 1.23% 16

Other funds holding AGMB

EFM
EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Casdin Capital's AGMB Position: Q2 2026 in Review

Casdin Capital held its AgomAb Therapeutics NV (AGMB) position steady in Q2 2026 at 1,550,000 shares worth $20.1M. The position accounts for 1.01% of the portfolio, ranked #20.

Casdin Capital first reported a position in AGMB in Q1 2026 and has held it in 2 quarters since. 34 funds tracked by Wall St. Rank hold AGMB as of Q2 2026.

  • Casdin Capital held 1,550,000 shares of AgomAb Therapeutics NV worth $20.1M as of Q2 2026.
  • Casdin Capital left its AgomAb Therapeutics NV share count unchanged in Q2 2026.
  • AgomAb Therapeutics NV made up 1.01% of Casdin Capital's portfolio in Q2 2026, its #20 holding.
  • Casdin Capital first reported a position in AgomAb Therapeutics NV in Q1 2026 and has held it in 2 quarters since.
  • 34 funds tracked by Wall St. Rank held AgomAb Therapeutics NV as of Q2 2026.

Based on Casdin Capital's 13F filing for Q2 2026, filed 14 Aug 2026.